Arrakis Therapeutics Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Arrakis Therapeutics's estimated annual revenue is currently $14.3M per year.
- Arrakis Therapeutics received $38.0M in venture funding in February 2017.
- Arrakis Therapeutics's estimated revenue per employee is $201,000
- Arrakis Therapeutics's total funding is $38M.
- Arrakis Therapeutics has 71 Employees.
- Arrakis Therapeutics grew their employee count by 48% last year.
- Arrakis Therapeutics currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Pricing|
|Vita Data Scien...||$10.3M||51||50%||N/A||N/A|
What Is Arrakis Therapeutics?
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. The company's TRYST and PEARL-seq platforms identify new RNA targets and drug candidates to treat diseases unaddressed by today's medicines. Arrakis is developing a proprietary pipeline of RNA-targeted small molecules focused on neurologic diseases, cancer, and rare genetic diseases. Arrakis was founded in 2015 by Russell Petter, Ph.D., Alan Walts, Ph.D., Henri Termeer and Raj Parekh, Ph.D. with a vision to create a proprietary, transformational discovery platform that identifies small-molecule drugs that act directly on disease-causing RNA. The company was established with seed funding provided by Advent Life Sciences and Henri Termeer. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Mass.keywords:N/A
Number of Employees
Employee Growth %
|Kristine McKinney||Associate Director, Target Biology & Translational Medicine||Email Available|
|Elizabeth Hawkins||Vice President, Finance & Strategy|
|Hernan Cuervo||Principal Ivestigator Consultant|
|Dan Koerwer||Chief Business Officer||Email Available|
|Neil Kubica||Director of RNA Biology|
|Heather Lounsbury||VP, Business and Technical Operations||Email Available|
|Donovan Chin||Director of Computational Drug Discovery||Email Available|
|Michael Seiler||Senior Scientist, Head Of Bioinformatics||Email Available|
|Meizhong Jin||Senior Director||Email Available|
|Jim Barsoum||Senior Vice President Research|
Arrakis Therapeutics News
BUSINESS WIRE)--Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small-molecule medicines ...
Arrakis Therapeutics Nabs $75 Million to Create a New Class of rSM ... Massachusetts-based Arrakis Therapeutics will focus its pipeline on ...
Arrakis is focusing on cancer because it has well-known, well-validated targets that have been considered undruggable. (Arrakis Therapeutics).
Arrakis Therapeutics Funding
Arrakis Therapeutics Executive Hires
|2017-02-28||Michael Gilman||Chairman/Chief Executive Officer||Article|